Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Stopped Primary analysis of the RMS phase 3 study (MS200527\_0082) resulted in the early termination of the study.

Conditions

• Relapsing Multiple Sclerosis

Interventions

• DRUG: Teriflunomide
• DRUG: Evobrutinib

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Collaborators

• [object Object]